AlphAIAlphAI — Financial news for AI agents
tradingview.com

BTIG reiterates Buy rating on CryoPort, $25 price target

BTIG maintained a Buy rating on CryoPort with a $25 price target, suggesting a 49% upside from its Sep 17 close. The company reported positive adjusted EBITDA for the first time since Q1 2023 and 15% year-over-year revenue growth in its Life Sciences Services segment. CryoPort supports 22 approved therapies and expects further growth from new facilities and clinical trials.

Original reporting
tradingview.com
Published Sep 18, 2026, 9:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG reiterates Buy rating on CryoPort, $25 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst upgrade reflects confidence in the company's turnaround and pipeline expansion.

02

Market read

The rating change could attract new investors and support CryoPort's share price toward the new target.

03

What to watch

Potential cash burn and reliance on a limited number of commercial therapy contracts.

Relevance 6/10Novelty 6/10Timing: today

Background

CryoPort recently posted its first positive adjusted EBITDA and 15% YoY revenue growth in its Life Sciences Services segment.

Market effects

Sector

Positive outlook may lift other life‑sciences service providers.

Regional

Limited to U.S. biotech and life‑sciences sector.

Global

Minor, confined to CryoPort and peers.

Counterpoint

What could challenge this read

The price target may be overly optimistic given CryoPort's small scale and execution risk.

Key entities

  • Company
    CryoPort

    Life‑sciences services provider (NASDAQ:CPRT).

  • Analyst
    BTIG

    Investment bank providing the Buy rating and $25 price target.

Read at source← All news

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

finance.yahoo.com
$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

SEC EDGAR 8-K
$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

yahoo.com
$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

SEC EDGAR 8-K
$IRENMed

IREN Says New AI Cloud Customers Are Prepaying 90% of the Chips

IREN (NASDAQ:IREN) announced a five-year AI Cloud contract with 90% prepayment on GPU capex, generating $22M annualized revenue per megawatt. Stock fell 16.95% to $18.03 but rose 10.65% after hours. Revenue rose 66% to $228M, with AI Cloud revenue at $200M. Cash decreased to $3.52B, net debt increased to $4.43B. IREN targets 90% GPU financing through prepayments.

247wallst.com
$CATXMedAI 9/10

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced…

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 • Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease con

SEC EDGAR 8-K